@Article {lui2003687，作者= {Lui，Macy Mei-Sze和TSE，Hung-Fat和Lam，David Chi-Leung和Lau，Kui-Kai和Chan，Carmen Wing-Sze和IP，Mary Sau-Man}，标题{连续正气道压力改善阻塞性睡眠呼吸暂停和高血压血管和血清心血管生物标志物}，Elocation-Id = {2003687}，年= {2021}，DOI = {10.1183 / 13993003.03687-13993003.03687-2020}，出版商= {欧洲呼吸社会}，摘要= {理由治疗阻塞性睡眠呼吸暂停（OSA）对心血管风险的减少的影响尚不清楚。本研究旨在研究连续正气道压力（CPAP）对OSA和高血压受试者的动态血压（BP）和亚临床心肌损伤的影响。方法具有高血压的受试者，需要至少三种抗高血压药物和中度严重的OSA注册了。符合条件的受试者随机（1：1）接受CPAP治疗或控制（无CPAP）八周。比较了动态BP和血清生物标志物的变化。根据昼夜节律BP模式进行了分层分析。结果结果九十个科目（75 \％男性;年龄，51 {\ Textpm} 8年;呼吸暂停 - 低管索引40 {\ TextPM} 8事件{\ TextHiodCentered} H-1，平均水平为3.4抗高血压药物[范围3 {\ TextEndash} 6]）被随机化。与对照组相比，CPAP治疗组均显示出24-H收缩型BP的显着降低（-4.4mmHg，95℃-8.7至-0.1，P = 0.046），24-H舒张性BP（-2.9 mmHg，95 \％CI -5.5至-0.2，p = 0.032），白天收缩压BP（-5.4 mmHg，-9.7至-1.0，p = 0.016）和白天舒张压bp（-3.4 mmHg，95 \％CI -6.1至 -0.8, p=0.012). CPAP treatment was associated with significant BP lowering only in non-dippers, but not in dippers. Serum troponin I (mean difference -1.74 pg{\textperiodcentered}mL-1, 95\% CI -2.97 to -0.5, p=0.006) and brain natriuretic peptide (-9.1 pg{\textperiodcentered}mL-1, 95\% CI -17.6 to -0.6, p=0.036) were significantly reduced in CPAP compared to control group.Conclusion In a cohort with OSA and multiple cardiovascular risk factors including difficult-to-control hypertension, short-term CPAP treatment improved ambulatory BP and alleviated subclinical myocardial injury and strain.FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Dr. Lui has nothing to disclose.Conflict of interest: Dr. Tse has nothing to disclose.Conflict of interest: Dr. LAM has nothing to disclose.Conflict of interest: Dr. Lau reports grants, personal fees and non-financial support from Boerhinger Ingelheim, grants and non-financial support from Pfizer, grants from Sanofi, grants from Amgen, non-financial support from Eisai, outside the submitted work.Conflict of interest: Dr. Chan has nothing to disclose.Conflict of interest: M. Ip has nothing to disclose.}, issn = {0903-1936}, URL = {//www.qdcxjkg.com/content/early/2021/03/25/13993003.03687-2020}, eprint = {//www.qdcxjkg.com/content/early/2021/03/25/13993003.03687-2020.full.pdf}, journal = {European Respiratory Journal} }